Caris Life Sciences Continues to Expand Its Impressive Roster of Leading Pathologists

Fast-Growing Biosciences and Diagnostic Company Adds More Than 30 Distinguished Experts to Its Industry-Leading Team


IRVING, Texas, Sept. 14, 2010 (GLOBE NEWSWIRE) -- Caris Life Sciences™, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic technologies, announced today that it has increased its team of field-leading pathologists by more than 20 percent over the past 10 months, adding in excess of 30 new experts since last October.

"We are very pleased that Caris has continued to successfully attract extraordinary talent from academia as well as the private sector," said Richard Lash, M.D., Chief Medical Officer. "In the past 10 months, we've hired distinguished experts in the fields of gastrointestinal, dermatologic, oncologic, hematologic and genitourinary pathology from some of the world's most prestigious institutions."

Caris Life Sciences now employs 79 pathologists, most of whom hold or have held academic professorships at the nation's leading medical centers. Also in keeping with the company's commitment to continuously improving the discipline of pathology, Caris Life Sciences pathologists have contributed significantly to research, with nearly 2,500 peer-reviewed career publications and book chapters to their collective credit.

The following are some of the experts who have recently joined the Caris team:

Sheryl L. Asplund, M.D., has more than 15 years of pathology expertise, completing her residency in Anatomic and Clinical Pathology at the Cleveland Clinic Foundation and a Hematopathology fellowship at the University of Texas Southwestern Medical Center in Dallas, where she later served as Assistant Professor of Pathology in the Division of Hematopathology. Over the past 15 years, she has also been a frequent invited lecturer at esteemed academic and professional conferences nationwide.

Karin Diane Berg, M.D., M.S., has held academic appointments at Johns Hopkins School of Medicine, serving as Assistant Professor of Pathology and Oncology, as well as the University of Vermont, College of Medicine. During her career, Dr. Berg has completed fellowships in Molecular Pathology and Gastrointestinal Pathology at Johns Hopkins School of Medicine.

Evan R. Farmer, M.D., is a world-renowned dermatopathologist, with more than 30 years of medical expertise in dermatology and dermatopathology. For the past four decades, Dr. Farmer has held professorships at Johns Hopkins University, Virginia Commonwealth University School of Medicine, Indiana University School of Medicine (Department Chairman) and Eastern Virginia Medical School (Dean and Provost, 2001 to 2004). His distinguished career also includes terms as President of the American Dermatological Association, Vice President of the American Academy of Dermatology and member of the Board of Directors of the American Board of Dermatology. He has published nearly 150 articles in peer-reviewed publications, as well as authored five books and nearly 40 book chapters.

Antoinette F. Hood, M.D., has led an extraordinary career in dermatology and dermatopathology, having held academic positions at Washington Hospital Center, George Washington University, Johns Hopkins University, Indiana University School of Medicine and Eastern Virginia Medical School, where she is Chair of Dermatology and Professor of Pathology and Anatomy. She has held leadership positions in several noted professional societies, including the American Academy of Dermatology, American Society of Dermatopathology, Women's Dermatologic Society and the American Dermatological Association. Her impressive career accomplishments also include authoring nine books, more than 40 book chapters and in excess of 140 peer-reviewed publications.

Mei-Yu Hsu, M.D., Ph.D., comes to Caris from Harvard Medical School, where she is currently serving as Associate Professor of Pathology. Since 1996, Dr. Hsu has frequently been invited to lecture at academic institutions and professional conferences both nationally and internationally and has 25 career peer-reviewed publications to her credit.

Amy E. Noffsinger, M.D., joins Caris from her position as Professor and Director of Surgical Pathology at the University of Cincinnati College of Medicine. Prior to that, Dr. Noffsinger served as Professor, Department of Pathology at the University of Chicago. With more than 20 years of teaching and research experience in pathology, she has taught and lectured extensively at distinguished academic and professional institutions around the world. Throughout her career, she has also published prolifically, with 70 career peer-reviewed articles and 18 books and book chapters to her credit.

Arash Radfar, M.D., Ph.D., most recently served as Associate Professor of Dermatology and Pathology and Director of Dermatopathology at the University of Maryland Medical Center in Baltimore. Over the past decade, Dr. Radfar has held professorships of Dermatology and Pathology at the University of Pittsburgh Medical Center PA and Boston University School of Medicine.

Yousef E. Tadros, M.D., has more than 25 years of medical expertise, recently serving as Clinical Assistant Professor of Pathology at the Medical College of Georgia. His training includes fellowships at Cedars Sinai Medical Center, Armed Forces Institute of Pathology and Tulane University Health Sciences Center, as well as residency training at Johns Hopkins. Dr. Tadros joins our newly formed Genitourinary Pathology faculty in Irving, Texas.

About Caris Life Sciences

Caris Life Sciences, a leading biosciences company, specializes in the development and commercialization of the highest quality anatomic pathology, molecular profiling and blood-based diagnostic technologies, in the fields of oncology, dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology. The company provides academic-caliber consultations for thousands of patients a day, through its industry-leading team of expert, subspecialty pathologists. Caris also offers advanced molecular analyses of patient samples through prognostic testing services and genomic, transcriptomic, and proteomic profiling to assist physicians in their treatment of cancer. Currently, Caris is developing the Carisome™ platform, a proprietary, blood-based technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. The company is headquartered in the Dallas metroplex, operates laboratories in the Dallas, Phoenix and Boston metro areas and is entering the European markets through its first international location, in Switzerland. For more information, visit www.carislifesciences.com.



            

Contact Data